Serotype 19A is the most common serotype causing invasive pneumococcal infections in children

Pediatrics

Volumn 125, Issue 3, 2010, Pages 429-436

  Kaplan, Sheldon L ^a   Barson, William J ^b   Lin, Philana L ^c   Stovall, Stephanie H ^d   Bradley, John S ^e   Tan, Tina Q ^f   Hoffman, Jill A ^g   Givner, Laurence B ^h   Mason Jr , Edward O ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Conjugate vaccine; Streptococcus pneumoniae; Surveillance

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; HOSPITAL ADMISSION; HUMAN; INFANT; INVASIVE PNEUMOCOCCAL INFECTION; MAJOR CLINICAL STUDY; MICROBIOLOGY; NEWBORN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS PNEUMONIA; UNITED STATES;

CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 77649115922     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-1702     Document Type: Article

References (28)

1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187-195
2. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746
3. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3):443-449
4. Black S, France EK, Isaacman D, et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(9):771-777
5. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction: eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57(6): 144-148
6. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192(11):1988-1995
7. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J. 2006;25(3):250-254
8. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006;42(7):907-914
9. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-1792
10. Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J. 2007;26(6):461-467
11. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(6):468-472
12. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196(9): 1346-1354
13. Moore M, Gertz RE, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7): 1016-1027
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. CLSI document M100-S19
15. Kaplan SL, Mason EO Jr, Barson WJ, et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics. 1998;102(3 pt 1):538-545
16. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298(15):1772-1778
17. Ongkasuwan J, Valdez TA, Hulten KG, Mason EO Jr, Kaplan SL. Acute pneumococcal mastoiditis in children and the emergence of multi-drug resistant serotype 19A Isolates. Pediatrics. 2008;122(1):34-39
18. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a children's hospital emergency department and urgent care center. Arch Pediatr Adolesc Med. 2004;158(7):671-675
19. Carstairs KL, Tanen DA, Johnson AS, Kailes SB, Riffenburgh RH. Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine. Ann Emerg Med. 2007; 49(6):772-777
20. Waddle E, Jhaveri R. Outcomes of febrile children without localising signs after pneumococcal conjugate vaccine. Arch Dis Child. 2009;94(2):144-147
21. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(12):1569-1576
22. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis. 2008;46(9):1346-1352
23. Nascimento-Carvalho C, Cardoso MR, et al. Penicillin/ampicillin efficacy among children with severe pneumonia due to penicillin resistant pneumococcus (MIC = 4 μg/mL). J Med Microbiol. 2009;58(pt 10): 1390-1392
24. Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Linares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother. 2009;64(3): 507-510
25. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis. 2009;199(6):776-785
26. Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis. 2008;14(2): 275-281
27. van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302(2):159-167
28. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007; 25(33):6164-6166